Cargando…

Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Hemoglobin Levels: A Meta-analysis of Randomized Controlled Trials

Background: This study aimed to explore the effects of sodium-glucose co-transporter 2 (SGLT2) on hemoglobin levels in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease. Methods: PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, the China National Knowledge I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qu, Wei, Yao, Li, Liu, Xiaodan, Xu, Tianhua, Tian, Binyao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994761/ https://www.ncbi.nlm.nih.gov/pubmed/33776773 http://dx.doi.org/10.3389/fphar.2021.630820

Ejemplares similares

Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
por: Ye, Yangli, et al.
Publicado: (2019)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Jing, Yuling, et al.
Publicado: (2022)

Appraisal of Non-Cardiovascular Safety for Sodium–Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials
por: Shi, Fang-Hong, et al.
Publicado: (2019)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
por: Armour, Sarah L., et al.
Publicado: (2022)

Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis
por: Tian, Lei, et al.
Publicado: (2022)

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
por: Li, Chun Xing, et al.
Publicado: (2023)

The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis
por: Kandeel, Mahmoud
Publicado: (2022)

Case Report: Coexistence of Anti-Glomerular Basement Membrane Disease, Membranous Nephropathy, and IgA Nephropathy in a Female PatientWith Preserved Renal Function
por: Qu, Wei, et al.
Publicado: (2022)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

A Description of Acute Renal Failure and Nephrolithiasis Associated With Sodium–Glucose Co-Transporter 2 Inhibitor Use: A VigiBase Study
por: Frent, Ioana, et al.
Publicado: (2022)

The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials
por: Wang, Dongmei, et al.
Publicado: (2022)

Sodium-Glucose Co-Transporter 2 Inhibitors Use Improves the Satisfaction With Anti-diabetic Agent Treatment: A Questionnaire-based Propensity Score-matched Study
por: Shi, Fang-Hong, et al.
Publicado: (2022)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
por: Sun, He, et al.
Publicado: (2023)

Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy
por: Ren, Changzhen, et al.
Publicado: (2021)

A model‐based meta analysis study of sodium glucose co‐transporter‐2 inhibitors
por: Yao, Xueting, et al.
Publicado: (2023)

Discovery and development of Factor Xa inhibitors (2015–2022)
por: Zheng, Wei, et al.
Publicado: (2023)

Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
por: Chen, Lu, et al.
Publicado: (2020)

Disparities in efficacy and safety of sodium-glucose cotransporter 2 inhibitor among patients with different extents of renal dysfunction: A systematic review and meta-analysis of randomized controlled trials
por: Hu, Suiyuan, et al.
Publicado: (2022)

Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism
por: Tan, Yunke, et al.
Publicado: (2021)

Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020)

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
por: Erythropoulou-Kaltsidou, Anastasia, et al.
Publicado: (2019)

Sodium-glucose co-transporter 2 inhibitors beyond diabetes
por: Williams, Dimity L, et al.
Publicado: (2022)

Sodium glucose co-transport 2 inhibitors for gout treatment
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2022)

Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
por: Pandey, Arjun K., et al.
Publicado: (2021)

Sodium–Glucose Cotransporter 2 Inhibitors Work as a “Regulator” of Autophagic Activity in Overnutrition Diseases
por: Fukushima, Kazuhiko, et al.
Publicado: (2021)

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
por: D'Onofrio, Nunzia, et al.
Publicado: (2021)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
por: Wu, Victor Chien-Chia, et al.
Publicado: (2021)

Current Use and Complementary Value of Combining in Vivo Imaging Modalities to Understand the Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors at a Tissue Level
por: van der Hoek, Sjoukje, et al.
Publicado: (2022)

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
por: Mascolo, Annamaria, et al.
Publicado: (2023)

Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes
por: Yang, Yinqiu, et al.
Publicado: (2020)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized
por: Wood, Stephen J, et al.
Publicado: (2022)

Sodium glucose co transporter 2 inhibitors and Ramadan: Another string to the bow
por: Kelwade, Jayant, et al.
Publicado: (2014)

Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight
por: Singh, Awadhesh Kumar
Publicado: (2015)

Sodium glucose co-transporter inhibitors – A new class of old drugs
por: Malhotra, Aneeta, et al.
Publicado: (2015)

Sodium glucose co-transporter-2 inhibitor: Patient safety and clinical importance
por: Senthilkumaran, Subramanian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_314om8krr95pdb9p45eo9v238h